164 related articles for article (PubMed ID: 6818701)
1. [Inhibitors suppression in hemophilia A with continued treatment of factor VIII].
Aznar JA; Jiménez C; García I; Martín G; Borrego D; Peiro A; Marty ML
Sangre (Barc); 1982; 27(4A):572. PubMed ID: 6818701
[No Abstract] [Full Text] [Related]
2. The importance of corticoids added to continued treatment with Factor VIII concentrates in the suppression of inhibitors in haemophilia A.
Aznar JA; Jorquera JI; Peiró A; Garcia I
Thromb Haemost; 1984 Apr; 51(2):217-21. PubMed ID: 6429884
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Lange D; Lazerson J
Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
[No Abstract] [Full Text] [Related]
4. Treatment of hemophilia complicated by inhibitors.
Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
[No Abstract] [Full Text] [Related]
5. Prophylaxis vs. episodic treatment to prevent joint disease in severe hemophilia.
Bernstein MJ
N Engl J Med; 2007 Nov; 357(20):2087; author reply 2087-8. PubMed ID: 18003967
[No Abstract] [Full Text] [Related]
6. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
Nilsson IM; Hedner U; Holmberg L
Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
[No Abstract] [Full Text] [Related]
7. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hemophilia with glycine-precipitated factor 8.
Abildgaard CF; Simone JV; Corrigan JJ; Seeler RA; Edelstein G; Vanderheiden J; Schulman I
N Engl J Med; 1966 Sep; 275(9):471-5. PubMed ID: 5917942
[No Abstract] [Full Text] [Related]
9. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
Kessler CM; Ludlam CA
Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
[No Abstract] [Full Text] [Related]
10. Home management of hemophilia A.
Van Eys J
J Tenn Med Assoc; 1971 May; 64(5):407-10. PubMed ID: 5091669
[No Abstract] [Full Text] [Related]
11. [Rehabilitation of children and young people with hemophilia].
Ahlberg A
Lakartidningen; 1968 Mar; 65(10):1026-8. PubMed ID: 5720698
[No Abstract] [Full Text] [Related]
12. The use of porcine factor VIII in France.
Negrier C
Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
[No Abstract] [Full Text] [Related]
13. Aspects of the management of hemophilia in childhood. Availability of newer concentrates of antihemophilic factor failitates management.
Strauss HS
R I Med J; 1966 Aug; 49(8):466-8. PubMed ID: 5222119
[No Abstract] [Full Text] [Related]
14. Dosage requirements for substitution therapy in hemophiliacs.
Scand J Haematol Suppl; 1980; 35():29-54. PubMed ID: 6770459
[No Abstract] [Full Text] [Related]
15. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
Aznar JA; Jorquera JI; Marty ML
Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
[No Abstract] [Full Text] [Related]
16. The use of porcine factor VIII in Japan.
Yoshioka A; Shima M; Morichika S; Terada S; Fukui H
Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769
[No Abstract] [Full Text] [Related]
17. [The value of AHF-prophylaxis].
Olin P
Lakartidningen; 1968 Mar; 65(10):1031-2 passim. PubMed ID: 5720700
[No Abstract] [Full Text] [Related]
18. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
Singer ST; Addiego JE; Reason DC; Lucas AH
Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
[TBL] [Abstract][Full Text] [Related]
19. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
[TBL] [Abstract][Full Text] [Related]
20. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
den Uijl IE; Fischer K
Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
